Matthew Shawn Morris Sells 44,340 Shares of Privia Health Group, Inc. (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) CEO Matthew Shawn Morris sold 44,340 shares of the firm’s stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $28.48, for a total transaction of $1,262,803.20. Following the sale, the chief executive officer now directly owns 121,739 shares in the company, valued at approximately $3,467,126.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $27.72 on Friday. The firm has a market capitalization of $3.19 billion, a P/E ratio of -252.00, a PEG ratio of 5.68 and a beta of 0.79. Privia Health Group, Inc. has a one year low of $17.99 and a one year high of $44.64. The company’s fifty day moving average is $26.08 and its two-hundred day moving average is $29.50.

Wall Street Analysts Forecast Growth

PRVA has been the topic of a number of research analyst reports. Truist Financial cut their price objective on shares of Privia Health Group to $41.00 in a report on Thursday, November 17th. The Goldman Sachs Group initiated coverage on shares of Privia Health Group in a report on Friday, February 3rd. They issued a “buy” rating and a $32.00 target price on the stock. BTIG Research cut their target price on shares of Privia Health Group from $45.00 to $40.00 in a report on Monday, January 9th. SVB Leerink cut their target price on shares of Privia Health Group from $46.00 to $39.00 and set an “outperform” rating on the stock in a report on Friday, November 11th. Finally, Stifel Nicolaus initiated coverage on shares of Privia Health Group in a report on Thursday, December 8th. They issued a “buy” rating and a $28.00 target price on the stock. Fourteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $38.73.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Privia Health Group by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,824,724 shares of the company’s stock worth $164,331,000 after purchasing an additional 321,734 shares in the last quarter. BlackRock Inc. boosted its position in shares of Privia Health Group by 16.8% during the 3rd quarter. BlackRock Inc. now owns 3,283,793 shares of the company’s stock worth $111,846,000 after purchasing an additional 471,296 shares in the last quarter. Millennium Management LLC boosted its position in shares of Privia Health Group by 183.8% during the 4th quarter. Millennium Management LLC now owns 2,996,072 shares of the company’s stock worth $68,041,000 after purchasing an additional 1,940,218 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Privia Health Group by 0.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,793,623 shares of the company’s stock worth $63,444,000 after purchasing an additional 18,752 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Privia Health Group by 71.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,204 shares of the company’s stock worth $80,960,000 after purchasing an additional 1,162,270 shares in the last quarter. 66.83% of the stock is currently owned by hedge funds and other institutional investors.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.